A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
A phase 2 trial of Trastuzumab deruxtecan and Bevacizumab in gastric & gastro-oesophageal junction cancer, run by AstraZeneca, active and no longer recruiting.
Overview
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors is a phase 2 interventional study registered as NCT06271837 by AstraZeneca, with 127 participants enrolled, started 2024-02-22 and due to reach its primary completion in 2027-02-10. Interventions recorded: Trastuzumab deruxtecan and Bevacizumab.
Similar pages
not linked directly; found by shared links- TrialTrastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialStudy of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialPh1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
Shares Daiichi Sankyo, Trastuzumab deruxtecan, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Shares Daiichi Sankyo, AstraZeneca and the tag pipeline.
- TrialA Study to Investigate the Effects of AZD0901 Monotherapy in Adult Participants With 2L+ Advanced or Metastatic Gastric or GEJ Adenocarcinoma Expressing CLDN18.2
Shares AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
Shares Daiichi Sankyo, Trastuzumab deruxtecan, AstraZeneca and the tag pipeline.
- TrialA Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors.
Shares Bevacizumab, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.
- TrialA Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Shares Trastuzumab deruxtecan, AstraZeneca, Gastric & gastro-oesophageal junction cancer and the tag pipeline.